Which medication is appropriate to prescribe for a 68-year-old client with schizophrenia?

Choice A reason: Aripiprazole is a second-generation antipsychotic with a favorable safety profile for older adults. It has a lower risk of extrapyramidal symptoms compared to first-generation agents and a lower risk of metabolic syndrome and significant weight gain compared to olanzapine. Its partial agonist activity at D2 receptors provides a balanced approach to managing symptoms with fewer anticholinergic effects. Choice B reason: Haloperidol is a high-potency first-generation antipsychotic. In the elderly, it carries a significantly high risk of extrapyramidal side effects, including tardive dyskinesia and parkinsonism. Due to the increased sensitivity of the aging brain and the risk of severe motor complications, it is generally not the first-line choice for a 68-year-old. Choice C reason: Olanzapine is associated with significant metabolic side effects, including weight gain, hyperglycemia, and dyslipidemia. In an older adult, these side effects can exacerbate or lead to cardiovascular disease and diabetes. While effective, the metabolic burden often makes it less desirable than cleaner alternatives like aripiprazole in the geriatric population. Choice D reason: Ziprasidone requires administration with a high-calorie meal (at least 500 calories) for adequate absorption, which can be a compliance challenge for some elderly patients. More importantly, it carries a risk of QTc interval prolongation, which requires careful cardiac monitoring in older adults who may have underlying heart conditions or are taking other QTc-prolonging medications.